Document Detail


Preclinical evaluation of the AKT inhibitor MK-2206 in nasopharyngeal carcinoma cell lines.
MedLine Citation:
PMID:  23143779     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
Nasopharyngeal carcinoma (NPC) is endemic to Asia and over 40 % of NPC tissues harbor PIK3CA amplifications. This study characterized the preclinical activity of MK-2206, an oral allosteric inhibitor of AKT in 6 NPC cell lines: C666-1, HK1, HONE-1-EBV, HONE-1, CNE-2 and HNE-1. Exposure to increasing concentrations of MK-2206 resulted in over 95 % of growth inhibition in all NPC cell lines with IC(50) values in the low micromolar range. Further experiments were performed in 3 representative NPC cell lines: CNE-2 (harbor PIK3CA mutation and most sensitive to MK-2206), C666-1 (carries PIK3CA amplification), and HONE-1-EBV (least sensitive to MK-2206). MK-2206 induced G(0)/G(1) cycle arrest in all 3 cell lines, but could induce apoptosis only in CNE-2 cells. MK-2206 significantly abrogated AKT signaling in all 3 cell lines by inhibiting the activation of AKT and its downstream effectors (FKHR, GSK3β and BAD). MK-2206 also reduced mTOR signaling by reducing activation of mTOR and its downstream 4E-BP1 and p70S6 kinase. MAPK activation was observed in HONE-1 and C666-1 cells, but not in CNE-2 cells following exposure to MK-2206. The addition of MK-2206 to cisplatin (but not with paclitaxel) has a supra-additive inhibitory effect on growth in vitro. In summary, MK-2206 can inhibit growth and abrogate AKT and mTOR signaling in NPC cell lines. This agent is currently being evaluated in a phase II study in metastatic NPC.
Authors:
Brigette B Y Ma; Vivian W Y Lui; Connie W C Hui; Cecilia P Y Lau; Chi-Hang Wong; Edwin P Hui; Margaret H Ng; S W Tsao; Yan Li; Anthony T C Chan
Related Documents :
23311629 - Key structure of brij for overcoming multidrug resistance in cancer.
24246849 - Diversin increases the proliferation and invasion ability of non-small-cell lung cancer...
23032069 - Abcg2 protects kidney side population cells from hypoxia/reoxygenation injury through a...
24266669 - Enhanced delivery of the rapta-c macromolecular chemotherapeutic by conjugation to degr...
23325839 - A highly conserved sequence associated with the hiv gp41 loop region is an immunomodula...
24659889 - Differential gene expression of chemokines in kras and braf mutated colorectal cell lin...
9137919 - Low concentrations of the phosphatase inhibitor okadaic acid stop tumor cell locomotion.
11911489 - Arsenite pretreatment attenuates benzo[a]pyrene cytotoxicity in a human lung adenocarci...
12059979 - Opposing roles for medial and central amygdala in the initiation of noradrenergic cell ...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2012-11-11
Journal Detail:
Title:  Investigational new drugs     Volume:  -     ISSN:  1573-0646     ISO Abbreviation:  Invest New Drugs     Publication Date:  2012 Nov 
Date Detail:
Created Date:  2012-11-12     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8309330     Medline TA:  Invest New Drugs     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Affiliation:
State Key Laboratory in Oncology in South China, Sir Y.K. Pao Centre for Cancer, Department of Clinical Oncology, Cancer Drug Testing Unit, Hong Kong Cancer Institute and Li Ka Shing Institute of Health Sciences, Chinese University of Hong Kong, Shatin, Hong Kong, China, brigette@clo.cuhk.edu.hk.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  A phase I, open-label, single-arm study for QT assessment of eribulin mesylate in patients with adva...
Next Document:  Combination with genistein enhances the efficacy of photodynamic therapy against human anaplastic th...